Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis

Overview of attention for article published in Frontiers in Pharmacology, January 2024

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter: 2 X users

Readers on

mendeley: 2 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 5,806 followers.

RT @FrontPharmacol: New Research: Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic revie…

11 Jan 2024

Reply Repost Favourite

New Research: Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis https://t.co/cxT95eF46x #pharmacology

10 Jan 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.